109 results about "Polar amino acids" patented technology

The present invention relates to a diagnostic agent for liver function, comprising a compound labelled with 13C at least at one specific position selected from the group consisting of the following (a) to (f): (a) galactose, glucose or xylose labelled with 13C at least at one specific position or a starch composed of glucose units labelled with 13C at least at one specific position; (b) a polar amino acid, heterocyclic amino acid, isoleucine or valine labelled with 13C at least at one specific position; (c) a carboxylic acid constituting the glycolytic pathway or the citric acid cycle, labelled with 13C at least at one specific position; (d) a fatty acid labelled with 13C at least at one specific position; (e) a glyceride labelled with 13C at least at one specific position; and (f) glycerol labelled with 13C at least at one specific position. According to the present invention, a diagnostic agent for liver function which imposes less physical burden on a subject, can give accurate test result immediately, and can be used safely without side effects is provided. The diagnostic agent of the invention is useful for evaluating the liver function of a subject at the time when the test is carried out.

The present invention relates to composite hydrogels comprising at least one non-peptidic polymer and at least one peptide having the general formula: Z—(X)_m—(Y)_n—Z′_p, wherein Z is an N-terminal protecting group; X is, at each occurrence, independently selected from an aliphatic amino acid, an aliphatic amino acid derivative and a glycine; Y is, at each occurrence, independently selected from a polar amino acid and a polar amino acid derivative; Z′ is a C-terminal protecting group; m is an integer selected from 2 to 6; n is selected from 1 or 2; and p is selected from 0 or 1. The present invention further relates to methods of producing the composite hydrogels, to uses of the composite hydrogels for the delivery of drugs and other bioactive agents/moieties, as an implant or injectable agent that facilitates tissue regeneration, and as a topical agent for wound healing. The present invention further relates to devices and pharmaceutical or cosmetic compositions comprising the composite hydrogels and to medical uses of the composite hydrogels.

A secreted proteolytic polypeptide comprising at least three non-polar or uncharged polar amino acids within the last four amino acids of the C-terminus of the polypeptide, encoding polynucleotides, expression vectors comprising the polynucleotides, host cell comprising the polynucleotides, methods for producing said polypeptide, and methods for using the polypeptide

The present invention provides an amphiphilic linear peptide and/or peptoid as well as a hydrogel that includes the amphiphilic linear peptide/peptoid. The amphiphilic linear peptide/peptoid is capable of forming a hydrogel. These peptides/peptoids include short amphiphilic sequences with a hydrophobic portion of aliphatic amino acids and at least one acidic, neutral, or basic polar amino acid. The amphiphilic linear peptide/peptoid is build up of non repetitive aliphatic amino acids, which may be in the L- or D-form. A plurality of such peptides/peptoids assembles to supramolecular helical fibers and forms peptide hydrogels after assembly. A corresponding hydrogel is formed in aqueous solutions at physiological pH and is thus useful for inter alia cell culture, tissue engineering, and drug release. Such hydrogels which are rigid, biocompatible and entrapping up to 99.9% of water are also well suited for applications utilizing electronic devices.

Provide are a peptide gel with practically sufficient mechanical strength and a self-assembling peptide capable of forming the peptide gel. The self-assembling peptide is formed of the following amino acid sequence: a₁b₁c₁b₂a₂b₃db₄a₃b₅c₂b₆a₄ where: a₁ to a₄ each represent a basic amino acid residue; b₁ to b₆ each represent an uncharged polar amino acid residue and/or a hydrophobic amino acid residue, provided that at least five thereof each represent a hydrophobic amino acid residue; c₁ and c₂ each represent an acidic amino acid residue; and d represents a hydrophobic amino acid residue.

Isolated peptides comprising no more than ten amino acids and having anti-bacterial properties are disclosed. In one embodiment the peptides have a consensus amino acid sequence X₁X₂X₃X₄X₅, wherein X₁ and X₅ comprise polar amino acids. In another embodiment, the peptides have a consensus amino acid sequence X₁X₂X₃X₄X₅, wherein X₂ and X₄ are asparagine (N) residues and X₃ is tryptophan (W). Compositions comprising same are also disclosed and uses thereof.

A novel human keratinocyte growth factor mutant features that the cysteine at its site No.102 is mutated to become non-polar amino acid and the deficient mutation takes place at its terminal N. It can prevent the generation of scar and fibrosis and promote the epiderm healing.

The invention belongs to the field of catalysts, and provides a silver impregnation liquid for ethylene oxide production through ethylene epoxidation, a silver catalyst and preparation methods thereof. The silver impregnation liquid for ethylene oxide production through ethylene epoxidation comprises the following components: 1) a silver-ammonia complex; 2) polar amino acid; 3) water; 4) an optional auxiliary agent; wherein based on the total weight of the impregnation liquid, the content of the polar amino acid is 0.05-60 wt%. Compared with the prior art, the uniformity of the silver catalystprepared by the method provided by the invention is improved, and the silver catalyst has higher selectivity and higher catalytic activity for the reaction of producing ethylene oxide by ethylene oxidation.